Categories: Nepal Cancer Center

BTF President Dr. Binay Shah Visits the Binaytara Foundation Cancer Center in Nepal

The BTF President Dr. Binay Shah recently visited the Binaytara Foundation Cancer Center (BTFCC) in Janakpur, Nepal. In addition to seeing patients at the Binaytara Foundation Cancer Center during his 3-week long trip to Nepal, Dr. Shah met with local leaders, partners, and other oncology professionals in Nepal to collaborate on the BTFCC’s projects and to discuss the current plans for the BTFCC.

The Binaytara Foundation Cancer Center was established in December 2018 in Janakpur, Nepal to provide cancer prevention, treatment, and palliative care services to the region’s more than 6 million residents. BTFCC is located in Nepal’s province 2. It is the only cancer hospital east of Kathmandu valley and west of Jhapa district – a densely populated geographic area which is home to nearly 20 million Nepalese.

The current hospital at the Binaytara Foundation Cancer Center is a 25-bed hospital operated out of a rented building. Plans are underway to expand this hospital to a 200-bed state-of-the-art center for excellence in cancer treatment, research and education. The Binaytara Cancer Trust, the sister non-profit of the Binaytara Foundation, which owns and operates the Binaytara Foundation Cancer Center in Janakpur, has purchased land to build the new cancer hospital. Ground-breaking of the new hospital is planned for April 15th, 2022.

Once the construction of the 200-bed hospital is completed and the hospital is fully operational, the BTFCC is expected to provide cancer care to nearly 20,000 new cancer patients annually. These patients will come from several districts in Nepal as well as the neighboring Indian state of Bihar which is about 14 miles from where the Binaytara Foundation Cancer Center is located. Like in Nepal, the state of cancer care in Bihar is also very poor. This hospital will serve these patients who have suffered due to lack of availability of cancer care and poor health awareness in general.

 

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

7 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

7 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

7 months ago